News / Taiwan / economic_daily
Jelikang Biotech Debuts on Emerging Stock Market with Fubon Securities Support
Health Technology · Biotechnology · economic_daily · 2026-08-31
7686
Jelikang Biotech officially listed on Taiwan's Emerging Stock Market on August 31, focusing on innovative minimally invasive medical aesthetics and tissue repair technology.
What Happened
Market Debut: Jelikang Biotech officially began trading on the Emerging Stock Market on August 31 with the support of Fubon Securities. This listing marks a significant milestone for the company, enhancing its visibility and providing greater flexibility for future capital raising and operational expansion.
Core Business: The company specializes in minimally invasive medical aesthetics and tissue repair, aiming to replace traditional, high-risk surgeries with safer, faster-recovery procedures. Its primary focus lies in two key technology platforms: soft tissue filling and minimally invasive lifting, which are applicable to breast shaping and reconstructive medicine.
R&D Capabilities: Jelikang has established a comprehensive R&D system that integrates product design, clinical validation, and intellectual property management. With a capital base of NT$501 million, the company utilizes a smart decision-making platform to optimize its development processes and improve success rates for its medical device pipeline.
Growth Strategy: Moving forward, the company plans to secure medical device certifications and expand its international distribution channels. Jelikang is also actively seeking strategic partnerships, joint development, or licensing opportunities with global pharmaceutical and medical device firms to accelerate the commercialization of its products.